MDMA-ASSISTED THERAPY FOR PTSD

LIVING CLINICAL LEDGER

Status: Living Content — Last Verified June 2026

Classification: Clinical Education Page — Investigational Treatment Overview

Authored by: Joseph W. LaFleur Jr., LICSW, MBA

Clinical Review: Joseph W. LaFleur Jr., DC LICSW #LC3000819

Source References: MAPS MDMA-Assisted Therapy Treatment Manual; C2PATT 2022 & PATT 2021 clinical training presentations; FDA Complete Response Letter coverage (2024–2026); MAPS DEA scheduling hearing archives (1984–1988); U.S. Department of Veterans Affairs trial announcement (2026)

Regulatory Status: MDMA remains a Schedule I controlled substance. MDMA-assisted therapy is not FDA-approved and is available to the public only through approved clinical trials.

This page is part of our commitment to evidence-based content with verifiable clinical provenance. Learn about our privacy and safety practices →

For Clients & Families Plain-language guide For Healthcare Professionals Clinical detail

MDMA-Assisted Therapy for PTSD

A plain-language guide to how this treatment works, where the law stands, and what comes next.

Before you read: MDMA-assisted therapy is not yet approved by the FDA. MDMA is still illegal outside of approved research. Right now, the only legal way to receive this treatment is by joining an approved clinical trial. This page is here to help you understand the treatment, not to offer it.

You may have seen headlines about MDMA helping people with PTSD, and the results from research studies have been genuinely strong. In those studies, roughly two out of three people no longer met the criteria for PTSD by the end of treatment.

Even so, there is a lot of confusion about what this treatment actually is and whether you can receive it. This guide explains it in clear terms: how the therapy is structured, why MDMA is currently illegal, why the FDA declined to approve it in 2024, and why many experts still believe it will likely be approved at some point in the future.

What the Treatment Looks Like

MDMA-assisted therapy is not just taking a pill. It is a full course of therapy that lasts about four to five months. It has three parts.

1. Getting Ready (3 sessions)

First, you meet with your therapy team three times. Each meeting is about 90 minutes. You get to know your therapists, learn what to expect, and build trust. You also talk about what you hope to heal. This part helps you feel safe before any medicine is used.

2. The Medicine Sessions (3 sessions)

Next come three longer sessions where you take the medicine. Each one lasts about eight hours. Two therapists stay with you the whole time. This is when the deep healing work happens. You may rest quietly with music and eyeshades, or you may talk. Both are fine.

3. Making Sense of It (9 sessions)

After each medicine session, you meet three more times to talk about what came up. This is called integration. It helps you turn your experience into real changes in your life. There are nine of these meetings in all.

Why the Long Sessions Matter

The eight-hour sessions give you time. There is no rush. The medicine slowly takes effect, builds up, and then fades. Your therapists follow your pace instead of pushing you.

One of the most helpful things MDMA does is make hard feelings easier to face. Trauma often makes people feel either panicked or numb, with little in between. MDMA seems to lower fear and raise a feeling of safety. This lets people look at painful memories without falling apart. Being able to stay present with hard feelings is a big part of healing.

The therapists do not steer or control the session. They trust that your own mind knows what needs to come up. Their main job is to keep you safe and to listen with care.

Why MDMA Is Illegal

This part surprises many people: MDMA was not always illegal.

In the 1970s and early 1980s, some therapists used MDMA legally to help people in therapy. They said it helped people open up and talk about hard things.

In 1984, the government moved to ban it. There were hearings to decide what to do. A judge who works for the DEA looked at all the evidence. He said MDMA had real medical use and should be placed in a less strict category so doctors could still use it. But the head of the DEA overruled his own judge and made MDMA fully illegal in 1986. It has stayed that way ever since.

This is why many experts say the ban was a mistake from the start. The science was pushed aside.

Why the FDA Said No in 2024

In 2024, a company asked the FDA to approve MDMA-assisted therapy. Despite the strong study results, the FDA declined and asked for more research first.

Importantly, the FDA did not say the treatment fails to work. Its concerns were about how the studies were designed and conducted:

• People could tell who got the medicine. MDMA has strong effects, so it was hard to keep the study fair. This made some results harder to trust.
• Safety gaps. The FDA wanted more complete safety records.
• Lasting results. The FDA wanted more proof that the benefits last over time.

One thing to know: even if the FDA had said yes, MDMA would not become legal for everyone. It would only be allowed in a specific form, under close medical care.

Why Many Experts Still Expect Approval

The 2024 "no" was a setback, but most people in the field see it as a delay, not the end. Here is why:

• The problems were about study design, not about whether the treatment helps.
• The company is running a new study and plans to apply again.
• In 2026, the Department of Veterans Affairs (the VA) started its own study of MDMA therapy for veterans, working together with the FDA.
• Many veterans' groups strongly support this research, because PTSD takes so many lives.

Still, this takes time. New studies often take three to five years. So approval may not come until later this decade. The direction looks hopeful, but there is no set date.

Have Questions About Trauma Treatment?

While MDMA therapy is not yet available outside of research, there are proven treatments for PTSD and trauma that can help right now. If you are struggling, you do not have to wait, and you do not have to figure it out alone.

Confidential Inquiry Call (202) 641-5335

District Counseling and Psychotherapy
2001 L Street NW, Suite 500
Washington, DC 20036
(202) 641-5335

Frequently Asked Questions

Is MDMA-assisted therapy FDA-approved?

No. As of 2026, MDMA-assisted therapy is not approved by the FDA. In August 2024, the FDA declined to approve the first application (submitted by Lykos Therapeutics) and requested an additional Phase 3 trial to further study the treatment's safety and efficacy. Research is ongoing and a resubmission is anticipated, but no approval currently exists.

Is MDMA legal?

No. MDMA has been classified as a Schedule I controlled substance in the United States since the late 1980s, meaning it is illegal to manufacture, possess, or distribute outside of federally authorized research. MDMA-assisted therapy is currently available to the public only through approved clinical trials.

Why did the FDA reject MDMA-assisted therapy if the trials were successful?

The rejection focused on methodological concerns rather than a conclusion that the treatment is ineffective. Key issues included functional unblinding — the difficulty of keeping participants unaware of whether they received MDMA given its noticeable effects — which raised questions about whether expectations influenced results. The FDA also cited gaps in safety data, selection bias from participants' prior MDMA use, and limited evidence of long-term durability.

Was MDMA always illegal?

No. MDMA was legal until the mid-1980s and was used by some psychiatrists and therapists as an adjunct to psychotherapy. The DEA first proposed scheduling it in 1984. After hearings, the DEA's own administrative law judge recommended the less restrictive Schedule III, citing accepted medical use and safety under supervision, but the recommendation was overruled and MDMA was placed in Schedule I.

When might MDMA-assisted therapy be approved?

There is no guaranteed timeline. Completing additional Phase 3 trials typically takes three to five years, so FDA reconsideration may not occur until the latter part of the decade. A VA-sponsored trial launched in 2026, coordinated with the FDA, may contribute important data.

How long does the MDMA-assisted therapy protocol take?

In clinical trials, the full protocol spans roughly four to five months and includes three 90-minute preparation sessions, three approximately eight-hour experiential (dosing) sessions, and nine 90-minute integration sessions.

References

This page draws on clinical training materials, expert presentations, and current regulatory reporting, including: the MAPS MDMA-Assisted Therapy Treatment Manual; Joanna Simundic, MDMA-Assisted Therapy Preparation Overview (C2PATT 2022); Dr. Chantelle Thomas, MDMA-Assisted Psychotherapy Therapeutic Process (C2PATT 2022); Sara Gael, MA, MDMA-Assisted Therapy Integration (C2PATT 2022); Dr. Phil Lister, Introduction to Co-Therapy (C2PATT 2022); Dr. Rick Doblin, PhD, MDMA-Assisted Therapy for PTSD: Past, Present, and Future; Dr. Brooke Balliet, Psychedelic Therapeutic Modalities (PATT 2021); MAPS, Making MDMA a Medicine: (Re)Scheduling for Schedule I Substances and DEA scheduling hearing archives (1984–1988); U.S. Department of Veterans Affairs, VA Launches MDMA-Assisted Mental Health Therapy Trial (2026); and FDA Complete Response Letter coverage in Psychiatric Times, HCPLive, and Pharmacy Times (2024–2026).

Disclaimer: This page is for educational purposes only and does not constitute medical advice. MDMA remains a Schedule I controlled substance in the United States, and MDMA-assisted therapy is not FDA-approved. This treatment should only be undertaken within approved clinical trials or appropriate legal and clinical frameworks. If you are experiencing PTSD or thoughts of self-harm, please consult a licensed mental health professional. In the U.S., the 988 Suicide and Crisis Lifeline is available 24/7 by calling or texting 988.

About the Author

Joseph W. LaFleur Jr. is a Licensed Independent Clinical Social Worker (LICSW, MBA) and Clinical Director of District Counseling and Psychotherapy at Joseph LaFleur and Associates, specializing in LGBTQ+ mental health, trauma, substance use, and psychedelic integration therapy. The practice provides affirming, evidence-based therapy services across DC, Maryland, Virginia, New Jersey, and New York.

To schedule a consultation, visit districtcounseling.com or call our office at 2001 L Street NW, Suite 500, Washington, DC 20036.

Understanding Trauma: The Neuroscience Behind Psychedelic-Assisted Healing

Meta Description: Explore the neuroscience of trauma and how polyvagal theory, the window of tolerance, and nervous system regulation inform psychedelic-assisted therapy. Learn about the six stages of trauma response and why body-based healing matters for PTSD recovery.

Keywords: trauma neuroscience, polyvagal theory psychedelic therapy, window of tolerance, nervous system regulation, PTSD brain science, vagus nerve healing, co-regulation therapy, fight flight freeze response, trauma treatment neuroscience

To understand why psychedelic-assisted therapy produces such remarkable outcomes for trauma, we must first understand what trauma actually does to the brain and body. Modern neuroscience has revolutionized our comprehension of how traumatic experiences become embedded in our physiology and why traditional talk therapy often falls short in addressing these deep-seated patterns.

The emerging field of psychedelic-assisted therapy does not merely offer new pharmaceutical tools. It provides powerful methods for working directly with the nervous system dysregulation that lies at the heart of traumatic suffering. Grasping this neuroscientific foundation transforms how clinicians approach healing and helps survivors understand their own experiences with greater compassion and clarity.

What Is Trauma? Beyond the Psychological Definition

Sigmund Freud provided one of the earliest clinical definitions of trauma as "a breach in the protective barrier against stimuli, which can lead to overwhelming feelings of helplessness." While this captures something essential, contemporary neuroscience has expanded our understanding significantly.

Dr. Arielle Schwartz, a clinical psychologist specializing in trauma and EMDR therapy, emphasizes that trauma fundamentally concerns powerlessness—"the experience of not having a choice about traumatic events, and the impact that has on one's sense of efficacy in the world throughout the lifespan."

At a neurobiological level, trauma represents much more than difficult memories. Traumatic experiences create what researchers now understand as impaired encoding of neural networks. A neural network is essentially a pattern of neurons that fire together in response to experiences, actions, and memories. When neural networks form under conditions of overwhelming threat, they encode differently than ordinary memories.

These traumatic neural networks share several characteristics. They tend to be isolated from positive experiences and adaptive information. They show asymmetrical activation patterns, lighting up more on the right side of the brain, making it difficult to gain perspective or access the "big picture." They resist integration with new information that might modify them. And critically, they continue influencing present-moment experience as though the threat is still ongoing.

Allan Schore, a leading researcher in attachment and neuroscience, describes traumatic memory as an "encapsulated self state"—a frozen configuration of mind, body, and emotion that gets triggered by current circumstances reminiscent of past trauma. When activated, this state dominates not just cognitive awareness but the felt sense of self, showing up in difficulty sleeping, racing heart, chronic anxiety, digestive problems, and the pervasive sense that something is wrong.

The Polyvagal Revolution

Perhaps no framework has transformed trauma treatment more profoundly than polyvagal theory, developed by neuroscientist Stephen Porges. This theory provides a map of the autonomic nervous system that explains both trauma symptoms and recovery pathways.

Traditional understanding divided the autonomic nervous system into two branches: the sympathetic nervous system (associated with "fight or flight" activation) and the parasympathetic nervous system (associated with "rest and digest" relaxation). Polyvagal theory reveals a more nuanced picture with three distinct neural circuits that evolved sequentially over millions of years.

The Three Autonomic Circuits

The oldest circuit, the dorsal vagal complex, evolved in ancient vertebrates and lives primarily below the diaphragm, connecting the vagus nerve to the organs of digestion. When we feel safe, this circuit supports healthy rest, digestion, and restoration. But under extreme threat, it can trigger an immobilization response—the freeze, collapse, or "playing dead" response seen across the animal kingdom.

The sympathetic nervous system, the second evolutionary development, enables mobilization for fight or flight. When we perceive danger, this system prepares us to defend ourselves or escape through increased heart rate, muscle tension, and heightened alertness.

The most recently evolved circuit, the ventral vagal complex, lives above the diaphragm and connects to the heart, lungs, throat, facial muscles, and inner ear. This is our social engagement system—the neural circuitry that enables connection, communication, and feeling safe with others. When active, we experience the "sparkle in the eye," natural prosody in voice, relaxed facial muscles, and the calm connectedness that characterizes healthy social interaction.

The Vagus Nerve as Information Highway

The vagus nerve, the tenth cranial nerve, serves as the primary communication channel between body and brain. A remarkable 80% of vagal nerve fibers are afferent—meaning they carry information from body to brain rather than brain to body.

This anatomical fact carries profound implications. As Dr. Schwartz observes, "all of our cognitive interventions are just working against the biology of the body" when we rely solely on top-down approaches. The body's state powerfully influences brain function, emotional experience, and even the capacity for rational thought. Creating safety from the ground up—through breath, movement, body awareness, and relational connection—works with rather than against our biology.

The ventral vagal circuit interconnects with other cranial nerves governing facial expression, middle ear function, vocalization, and swallowing. This explains why trauma survivors often show changes in facial expression, have difficulty with prosody (the musical quality of speech), may struggle to hear speech clearly in noisy environments, and sometimes have difficulty swallowing.

The Social Engagement System

The social engagement system represents humanity's primary defense against threat. Before fighting or fleeing, mammals including humans first attempt to establish safety through social connection—reaching out for help, signaling distress, seeking comfort.

This system's facial and vocal expressions communicate safety or danger to others while simultaneously reading those cues from the environment. We instinctively orient toward faces, seek eye contact, and feel calmed by soothing voices. This is not weakness or dependence—it reflects millions of years of evolutionary wisdom about survival within social groups.

When the social engagement system is online and functioning well, it provides a gentle, refined brake on sympathetic activation. Like a skilled driver approaching a yellow light, it allows smooth regulation—accelerating or decelerating as circumstances require. This flexibility and responsiveness is the hallmark of a well-regulated nervous system.

The Six Stages of Trauma Response

Building on polyvagal theory, researchers have mapped a sequence of defensive responses that unfold as threat intensifies. Understanding this sequence helps clinicians recognize where clients are stuck and helps survivors understand their own responses with greater self-compassion.

Freeze: The Initial Orienting Response

The freeze response marks the initial recognition of potential threat—the proverbial deer in headlights. This sympathetically-activated pause allows the organism to orient to danger and gather information before committing to action. It is not yet the parasympathetic immobilization of later stages but rather an alert, watchful suspension of activity.

Flight: Mobilizing for Escape

If the threat is confirmed and escape seems possible, the system mobilizes for flight. This sympathetic response pumps blood to large muscles, sharpens senses, and suppresses non-essential functions like digestion. The individual feels the urge to run, to get away, to create distance from danger.

Fight: Mobilizing for Defense

When flight is not possible or the threat is unavoidable, the sympathetic system channels its energy toward fighting back. Anger, aggression, and protective impulses emerge as the organism prepares to defend itself. This response requires the capacity to mobilize significant energy while remaining sufficiently organized to direct it effectively.

Fright: Oscillation and Instability

When neither flight nor fight succeeds, the nervous system enters a destabilized state called "fright"—rapid alternation between sympathetic activation and parasympathetic shutdown. The individual may feel dizzy, nauseous, simultaneously panicky and exhausted. This oscillation represents the system's increasingly desperate attempts to find a successful defensive strategy.

Clinicians must recognize fright responses because they indicate the system is becoming overwhelmed. Therapeutic interventions at this point should focus on helping the client "climb the polyvagal ladder" back toward ventral vagal regulation—grounding, orienting to present safety, and reestablishing relational connection.

Flag (and Fawn): Submission and Appeasement

The flag or "submit" response involves the parasympathetic system becoming dominant while the individual attempts to forestall attack through appeasement. This connects to what many trauma therapists now call the "fawn" response—trying to please or care for an attacker's emotional or physical needs to avoid harm.

The fawn response reveals a deep conflict between the fear-driven need for survival (which pushes toward flight or fight) and the attachment-driven need for connection. Many trauma survivors, particularly those who experienced childhood abuse from caregivers, developed fawning as their primary defensive strategy. They learned to monitor others' emotional states hypervigilantly and suppress their own needs to maintain relationships upon which their survival depended.

Faint: Complete Shutdown

At the extreme end of the defensive cascade, the dorsal vagal system produces complete immobilization—a faint response that resembles death. Heart rate and blood pressure drop dramatically. The individual may literally lose consciousness or enter a dissociative state of profound disconnection from body and environment.

This response evolved because playing dead can sometimes cause a predator to lose interest. It also provides a kind of analgesic protection against the full horror of an inescapable attack. But when this response becomes habitualized, it creates profound difficulties in daily functioning, relationships, and the capacity to feel alive.

The Window of Tolerance

The concept of the window of tolerance, popularized by Dan Siegel, describes the optimal zone of nervous system arousal within which an individual can respond effectively to sensations, emotions, and experiences.

Within the window, a person has access to both emotional responsiveness and rational thought. They can tolerate distress without being overwhelmed by it. They can connect with others while maintaining a sense of self. They can reflect on experience rather than merely reacting to it.

Above the window lies hyper-arousal: anxiety, panic, hypervigilance, racing thoughts, difficulty calming down. Below the window lies hypo-arousal: numbness, disconnection, exhaustion, difficulty feeling anything, dissociation.

Dissociation Reconsidered

From a somatic perspective, dissociation encompasses any state that lives outside the window of tolerance. This broader definition recognizes that both hyper-arousal states (being flooded with overwhelming sensation and emotion) and hypo-arousal states (being cut off from sensation and emotion) represent dissociated states—departures from integrated, embodied presence.

This understanding has important clinical implications. A client who becomes emotionally flooded is not necessarily more "in touch" with their experience than one who shuts down. Both need help returning to the window where actual processing and integration can occur.

Building a Broader Window

The goal of trauma treatment is not merely to keep clients within their current window of tolerance. Rather, the aim is to expand that window—building capacity to be present with a fuller range of human experience including intense emotions, difficult memories, and challenging sensations.

This expansion happens gradually through carefully titrated exposure to distressing material while maintaining connection to safety and resources. We cannot learn to tolerate anxiety by avoiding everything that evokes it. We build capacity by learning to approach fear, jitteriness, and restlessness without being overwhelmed—stretching the edges of what we can be present with.

Neuroception: The Body's Threat Detection System

Porges introduced the term "neuroception" to describe the nervous system's continuous, largely unconscious evaluation of safety and danger. Every moment, neural circuits are scanning the body, the environment, and other people for cues indicating whether situations are safe, dangerous, or life-threatening.

This evaluation occurs faster than conscious thought and often drives responses before we are aware of them. The heart racing upon entering a particular building. The shoulders tensing around certain people. The gut twisting in anticipation of certain conversations. These responses reflect neuroceptive evaluation that may or may not match present reality.

When Neuroception Misleads

Research shows that individuals with PTSD are more likely to perceive neutral faces as threatening, to read sadness as fear, and to detect danger where none exists. These are not failures of intelligence or rationality—they are conditioned neuroceptive responses shaped by traumatic experience.

The system essentially becomes calibrated for danger, defaulting to threat detection in ambiguous situations. This makes evolutionary sense: in genuinely dangerous environments, false positives (detecting danger that is not there) cost less than false negatives (missing danger that is there). But when the environment is actually safe, this calibration creates suffering and dysfunction.

Bringing Perception to Neuroception

Healing involves bringing conscious awareness to automatic neuroceptive responses. "My heart's racing, my palms are sweaty, I'm swallowing more, my mouth got dry—I'm having an anxiety response. Now I can ask: Is this accurate? Is there really a threat going on? Or is this in response to a memory? Is this me perceiving something that's actually not a threat?"

This capacity for reflection—observing our own nervous system states—creates space between stimulus and response. It does not eliminate dysregulation but allows us to recognize it, make choices about it, and ultimately develop different responses.

Co-Regulation: We Hold More Together

One of the most important principles from interpersonal neurobiology is that regulation develops within relationships. Infants do not have the neural development to regulate themselves; they require attuned caregivers whose regulated nervous systems provide a template and a container for developing regulation.

This relational pattern continues throughout life. We are not designed to regulate alone. Our nervous systems are inherently social, continuously influenced by the nervous systems of those around us. When we are with well-regulated others, our own capacity for regulation expands. When we are with dysregulated others, we tend to become dysregulated ourselves.

The Therapeutic Relationship as Regulatory Container

In psychotherapy, co-regulation describes the therapist's capacity to maintain ventral vagal regulation while being present with a client's distress. This is not about the therapist being unaffected or emotionally distant. Rather, it involves the therapist sharing their capacity for regulation so that, in their presence, the client actually has a broader window.

Dr. Schwartz captures this beautifully: "When you are with an individual, and they start to go out of their window, they're feeling distressed, it's not that we ultimately want to restrict them, or put them back into the window... what we can do is share our capacity so that in the presence of us, they actually have a broader window."

Through repeated experiences of co-regulation, clients gradually internalize what they experience relationally. The external regulatory support becomes internal regulatory capacity. Someone who had no consistent co-regulator in childhood can develop self-regulation through adult relationships that provide what was missing.

Therapist Regulation as Foundation

Co-regulation is bidirectional. A dysregulated therapist cannot provide regulatory support to clients regardless of their technical skills or theoretical knowledge. This places enormous importance on therapist self-care, personal therapy, and ongoing attention to their own nervous system states.

This principle takes on heightened significance in psychedelic-assisted therapy, where sessions last many hours and involve working with intensely activated material. Therapists who cannot maintain their own regulation during these extended sessions will struggle to provide the consistent holding environment clients need.

Three Stages of Trauma Treatment

Contemporary trauma treatment typically proceeds through three overlapping phases, each with distinct goals and interventions.

Stage One: Safety and Stabilization

The first stage focuses on establishing safety in the present and building internal resources. This includes developing awareness of nervous system states, learning grounding and containment skills, building the capacity to return to the window of tolerance, and establishing a safe therapeutic relationship.

Without adequate safety and stabilization, attempts to process traumatic material often lead to flooding or shutdown rather than healing. The client needs a "home base" of relative regulation to return to when distressed.

Stage Two: Processing Traumatic Material

With adequate resources in place, the second stage involves carefully approaching traumatic memories and their associated emotional, somatic, and cognitive elements. This work happens at the edges of the window of tolerance—enough activation to access the material, not so much as to overwhelm.

Effective processing involves the integration of traumatic neural networks with adaptive information: the recognition that the threat is past, that the current environment is safe, that one survived, that resources and support now exist. This integration changes the neural network itself rather than merely providing cognitive insight.

Stage Three: Integration and Reconnection

As traumatic material becomes processed, the third stage involves integrating changes into daily life, rebuilding or developing healthy relationships, reconnecting with meaning and purpose, and establishing sustainable wellbeing.

These stages rarely proceed in perfect linear fashion. Treatment may cycle through all three multiple times, moving between resource-building and processing as the work requires. The three-stage model provides a map rather than a rigid protocol.

Why Psychedelics Transform Trauma Treatment

This neuroscientific framework illuminates why psychedelic-assisted therapy proves so effective for trauma. These medicines work directly with the systems that trauma disrupts.

MDMA substantially expands the window of tolerance, allowing access to traumatic material without triggering the overwhelming fight, flight, or freeze responses that normally prevent processing. Participants describe being able to feel pain without shutting down, experience rage without losing control, or witness themselves beginning to dissociate while remaining present.

Psilocybin disrupts the rigid neural patterns of the default mode network—the brain's self-referential processing system that becomes hyperactive in depression and trauma, trapping people in repetitive negative thinking. This disruption creates the possibility for new patterns to form.

Ketamine interrupts the neurochemical cascades that maintain depressive states, providing rapid relief while creating windows of neuroplasticity during which new learning can occur.

All these medicines, when combined with skilled therapeutic support, create conditions where the nervous system can complete its interrupted defensive responses, integrate fragmented experiences, and establish new patterns of regulation. They provide pharmacologically supported access to states that might otherwise take years of careful therapy to achieve—if they could be achieved at all.

Implications for Practice

Understanding trauma neuroscience transforms how clinicians approach psychedelic-assisted therapy.

It emphasizes the importance of bottom-up interventions—working with breath, body awareness, movement, and relational attunement—rather than relying exclusively on cognitive approaches. The 80/20 ratio of vagal afferent fibers reminds us that the body leads the brain more than the reverse.

It highlights the therapeutic relationship as itself a regulatory intervention. The quality of presence therapists bring matters as much as the techniques they employ. Co-regulation provides the container within which healing becomes possible.

It encourages patience with the pace of healing, recognizing that nervous system change occurs through repeated experience rather than insight alone. Information alone rarely changes deep patterns; embodied experience does.

And it supports appropriate humility about the complexity of trauma and healing. The nervous system's defensive strategies developed for good reasons and served survival functions. Approaching them with curiosity and respect, rather than trying to override or eliminate them, creates the conditions for genuine transformation.

Key Takeaways

• Trauma creates impaired neural networks that resist integration with adaptive information and continue influencing present experience as though threat is ongoing

• Polyvagal theory describes three autonomic circuits: ventral vagal (social engagement), sympathetic (fight/flight), and dorsal vagal (rest/collapse)

• The six stages of trauma response (freeze, flight, fight, fright, flag/fawn, faint) represent increasingly desperate defensive strategies

• The window of tolerance describes the optimal zone for processing; trauma treatment aims to expand this window through carefully titrated exposure

• Neuroception—the body's automatic threat detection—can become miscalibrated through trauma, detecting danger where none exists

• Co-regulation in the therapeutic relationship expands clients' capacity for regulation and eventually becomes internalized as self-regulation

• Psychedelics work directly with these neurobiological systems, expanding the window of tolerance and enabling nervous system completion of interrupted defensive responses

References

This article draws on clinical training materials and expert presentations including:

• Dr. Arielle Schwartz, Clinical Psychologist and EMDR Consultant, Introduction to the Neuroscience of Trauma, PATT 2021 Training

• Dr. Arielle Schwartz, Applied Trauma Neuroscience Basic Skills, C2PATT 2022 Training

• Dr. Veronika Gold, Ketamine-Assisted Therapy for Depression, C2PATT 2022 Training

• Jack McCowan, LPC, Introduction to Therapist Self-Regulation, PATT 2021 Training

• Rosalind Watts, PhD, Psilocybin and the ACE Model for Depression, C2PATT 2022 Training

• Stephen Porges, PhD, Polyvagal Theory (referenced throughout training materials)

• Dan Siegel, MD, Window of Tolerance concept (referenced throughout training materials)

• Allan Schore, PhD, research on attachment and encapsulated self states (referenced in training)

Disclaimer: This article is for educational purposes only and does not constitute medical advice. Psychedelic-assisted therapy should only be conducted by trained professionals within appropriate legal and clinical frameworks.

Ketamine-Assisted Psychotherapy: A Comprehensive Guide to Treatment Options, Routes of Administration, and What to Expect

Meta Description: A thorough exploration of ketamine-assisted psychotherapy, including IV, intramuscular, sublingual, and intranasal routes of administration, dosing protocols, safety considerations, and how therapy integrates with treatment.

Keywords: ketamine-assisted psychotherapy, KAP, ketamine therapy, IV ketamine, ketamine infusion, ketamine for depression, ketamine treatment, ketamine routes of administration, sublingual ketamine, intramuscular ketamine

Introduction: Understanding Your Ketamine Treatment Options

Ketamine has emerged as one of the most promising treatments for depression, anxiety, PTSD, and other mental health conditions that haven't responded to conventional approaches. Unlike other psychedelic-assisted therapies still working through FDA approval, ketamine is already legally available through licensed medical providers, making it accessible to patients now.

However, ketamine treatment isn't one-size-fits-all. Multiple routes of administration exist, each with different characteristics, intensities, and applications for therapy. Understanding these options helps patients make informed decisions and helps therapists know what to expect when supporting clients through ketamine experiences.

The Three-Person Relationship

Before diving into specifics, it's crucial to understand how ketamine-assisted psychotherapy works as a collaborative model. As Dr. Meghan Oxley, an emergency medicine physician who co-founded an integrative ketamine clinic, explains: "The relationship with ketamine in the patient is always three people: it's the patient, the therapist, and the provider."

This triad matters because therapists don't make medical decisions about ketamine—that requires medical training and licensure. But therapists do need to understand enough about ketamine's medical aspects to assess whether clients might be appropriate candidates and to support them effectively during and after treatment.

How Ketamine Works: Core Mechanisms

Understanding ketamine's mechanism of action helps explain why different routes of administration create different experiences.

Ketamine primarily works by blocking NMDA glutamate receptors in the brain. This has several therapeutic effects. First, it promotes neuroplasticity—the brain's ability to form new connections. In depression, there's typically a loss of synaptic connections; ketamine helps reverse this by stimulating BDNF (brain-derived neurotrophic factor) and encouraging new neuronal growth.

Second, ketamine quiets the default mode network, the brain system associated with self-referential thinking and rumination. As Dr. Oxley describes it: "Their thoughts are like really woven together very tightly, and ketamine kind of relaxes that tightness of the thought. And now, as a therapist, you're trying to help them weave a new way of thinking, a new narrative—and there's a lot of room to get the threads in."

This combination of neuroplasticity and loosened cognitive patterns creates a window of opportunity for therapeutic work that's otherwise difficult to access.

Routes of Administration: An Overview

Ketamine can be administered through several routes, each creating a different profile of intensity, duration, and experience:

IV (Intravenous): Administered through a drip over 40-60 minutes. Most studied route with the most robust scientific literature. Gradual onset allows for dose adjustments during session.

IM (Intramuscular): Injection into muscle. Faster onset, more intense peak, easier to administer but less controllable once given.

Sublingual/Oral: Dissolves under tongue or swallowed. Lower bioavailability, milder experience, longer duration. Most accessible and lowest-risk option.

Intranasal: Sprayed into nose. Includes FDA-approved esketamine (Spravato) and compounded ketamine sprays. Moderate intensity.

The intensity of any route can be modulated by dose—you can make IV as intense as IM by increasing the dose, or make IM milder by using less. However, each route has characteristic patterns that shape the therapeutic experience.

IV Ketamine: The Gold Standard for Medical Treatment

IV ketamine is the most thoroughly researched route, with hundreds of published studies. The standard protocol typically involves six to eight infusions over three to four weeks, followed by maintenance boosters every four to six weeks.

A standard dose ranges from 0.5 mg/kg to 1.2 mg/kg delivered over 40-60 minutes. Interestingly, as Dr. Oxley notes, this protocol wasn't derived through rigorous comparative research but was borrowed from electroconvulsive therapy (ECT) scheduling. "They just modeled the infusion series after ECT... That protocol is helpful but it wasn't scientifically studied to the tee."

This means there's flexibility. Many patients do well with once-weekly infusions rather than more aggressive scheduling.

Advantages of IV: The gradual onset over 40-60 minutes allows providers to adjust—they can turn the drip up, down, or off entirely based on how the patient is responding. This makes IV particularly suitable for patients with histories of difficult psychedelic experiences, significant PTSD where they might "get into the woods," or high sensitivity to medications where finding the right dose requires titration.

What the experience is like: Patients start to feel effects within a few minutes as the drip begins, building gradually to peak and then clearing within two to three minutes after the infusion stops. The experience can range from mild (like "one glass of wine") to profound cosmic experiences, even at the same dose in different people. This variability is characteristic of ketamine.

Intramuscular (IM) Ketamine: For Deeper Psychotherapeutic Work

Intramuscular ketamine is often the choice for ketamine-assisted psychotherapy (KAP) because it creates a longer, more immersive experience conducive to deep therapeutic work. Sessions typically last around three hours.

Key characteristics: IM ketamine produces a faster onset and more intense peak than IV. The patient receives the entire dose at once (unlike the gradual IV drip), which creates a more defined "journey" with clearer beginning, middle, and end.

Scientific literature on IM ketamine for mental health is more limited—Dr. Oxley notes only five published studies using doses ranging from 0.5 to 2 mg/kg.

Important safety consideration: "IM ketamine is actually in many ways less safe than IV ketamine," Dr. Oxley emphasizes, "because the patient's getting all of the dose at once instead of over an hour, and then you can't take it back. With IV, you can turn it off... with IM ketamine, you're in it until they're done."

Higher doses (above 1 mg/kg) should be administered in settings with resuscitation capability and personnel trained in ACLS (Advanced Cardiac Life Support). Lower doses (0.5 mg/kg) carry significantly less risk.

Therapist considerations: IM sessions are emotionally demanding for therapists as well. Many practices limit therapists to one KAP session per day, supplemented by traditional therapy hours. "Our therapists have a hard time doing two IM sessions in one day. They find it to be emotionally quite exhausting."

Sublingual and Oral Ketamine: Accessibility and Safety

Sublingual ketamine—where the medication dissolves under the tongue—represents the most accessible and lowest-risk option. It comes in several forms: troches (small lozenges the consistency of a Skittle), rapid-dissolving tablets (RDTs, like Smarties candy), or liquid that can be held in the mouth.

Key characteristics: Bioavailability is significantly reduced with sublingual/oral administration because much of the ketamine is metabolized by the liver before reaching the brain. This creates milder, shorter experiences with a gentler onset curve.

As Dr. Oxley notes: "Sublingual ketamine is very cheap, very easy, has a nice dosing curve, has a very low likelihood of adverse outcomes because the medicine concentration does not peak rapidly like it does with IM, which is one of the problems—that really rapid onset is why you run into safety issues."

Therapeutic applications: Sublingual ketamine can be useful for:

• Patients beginning ketamine treatment who need gentler introduction

• At-home maintenance between clinic sessions

• Patients who want support for therapy but don't need or want intense psychedelic experiences

• Cost-conscious treatment (compounded sublingual ketamine is typically much less expensive than IV)

Intranasal Ketamine: Including Esketamine (Spravato)

Intranasal ketamine falls between sublingual and IM in intensity. This includes FDA-approved esketamine (Spravato)—the S-enantiomer of ketamine—which is administered in certified healthcare settings.

Compounded intranasal ketamine (using racemic ketamine) is also used in some practices. The experience profile is relatively short, similar to or slightly more intense than sublingual.

What Happens During a Ketamine Session

Regardless of route, ketamine produces altered states of consciousness that can include:

Physical effects: Patients often feel "heavy" or disconnected from their body. Coordination is impaired, which is why patients should not drive for several hours after treatment. Some experience nausea, though this is typically manageable.

Perceptual changes: Visual and auditory perception may shift. Some patients report geometric patterns, enhanced colors, or a dream-like quality to their experience.

Dissociation: Ketamine can produce a sense of separation from ordinary experience—feeling like an observer of one's own thoughts, emotions, or memories. This can facilitate therapeutic processing by allowing difficult material to be approached with less overwhelming intensity.

Transpersonal experiences: At higher doses, some patients report experiences of ego dissolution, interconnection, or spiritual significance similar to those seen with classical psychedelics.

The specific content and quality of ketamine experiences varies enormously between individuals and even between sessions in the same individual.

The Therapeutic Frame: How Psychotherapy Integrates

What distinguishes ketamine-assisted psychotherapy from medical ketamine treatment is the intentional integration of psychotherapy throughout the process.

Preparation sessions establish therapeutic rapport, assess the patient's history and goals, and prepare them for what to expect. The therapist helps the patient develop intentions for their ketamine work.

During the session, a therapist remains present to provide support, offer reassurance if difficult material emerges, and witness the experience. The therapist follows the patient's process rather than directing it.

Integration sessions afterward help patients make meaning of their experiences, connect insights to their lives, and translate acute experiences into lasting change.

As Dr. Veronika Gold notes, some patients who don't respond to IV ketamine alone do respond when psychotherapy is added, "because some of the patients who did not respond to the IV treatment maybe respond to the psychotherapeutic process and processing some of the underlying issues."

Choosing the Right Route

Route selection depends on multiple factors:

Treatment goals: Is the primary goal rapid symptom relief for severe depression? IV or IM might be appropriate. Is the goal deep psychological processing? IM with psychotherapy support may be ideal. Is the goal affordable maintenance? Sublingual could work well.

Patient factors: Has the patient had difficult psychedelic experiences before? IV offers more control. Is the patient highly sensitive to medications? Start gentler with sublingual or low-dose IV. Does the patient have medical conditions affecting certain routes?

Setting factors: What routes can your clinic safely administer? IM at higher doses requires resuscitation capacity. Sublingual can be administered in simpler settings.

Cost considerations: IV and IM sessions in clinical settings are typically more expensive than sublingual home programs, though insurance coverage varies.

What Patients Should Know

For those considering ketamine treatment:

It requires medical supervision. Ketamine should only be used under the care of licensed medical providers who can assess appropriateness, monitor for adverse effects, and adjust treatment as needed.

It's not a one-time fix. While some patients experience significant relief after a single session, most benefit from a series of treatments plus integration work. Maintenance may be needed long-term for some conditions.

Set and setting matter. The environment in which ketamine is administered affects the experience. Clinical settings with trained staff, comfortable surroundings, and appropriate therapeutic support optimize outcomes.

Integration is crucial. The window of neuroplasticity ketamine opens needs to be used—through therapy, lifestyle changes, and applying insights. Without integration, benefits may be temporary.

Key Takeaways

• Ketamine works by promoting neuroplasticity and quieting rigid brain patterns, creating a window for therapeutic change

• IV ketamine is most studied and allows dose adjustment during sessions; standard protocol is 6-8 infusions over 3-4 weeks

• IM ketamine produces more intense experiences suited for deep psychotherapeutic work but requires appropriate safety measures

• Sublingual ketamine is most accessible and lowest-risk, with milder experiences suitable for many applications

• The "three-person relationship" between patient, therapist, and medical provider is essential

• Route selection depends on treatment goals, patient factors, setting capabilities, and cost

• Integration with psychotherapy appears to enhance outcomes beyond medical ketamine alone

References and Expert Sources

This article draws on presentations and research from:

• Dr. Meghan Oxley, M.D. — Emergency medicine physician; Founder of Michigan Progressive Health; Board member of the American Society of Ketamine Physicians, Psychotherapists and Practitioners (ASKP3)

• Dr. Sandhya Prashad, M.D. — Psychiatrist specializing in interventional psychiatry and IV ketamine; ASKP3 board member

• Dr. Veronika Gold, Ph.D. — Ketamine-assisted psychotherapy practitioner and educator

• American Society of Ketamine Physicians, Psychotherapists and Practitioners — Professional organization guidelines

This article is for educational purposes only and does not constitute medical advice. Ketamine should only be used under the supervision of licensed healthcare providers. If you are considering ketamine treatment, consult with a qualified medical professional to determine if it's appropriate for your situation.

Guide to Psychedelic Integration Therapy in Washington DC

Psychedelic Integration Therapy in Washington DC | Ketamine & Psilocybin

By Joseph W. LaFleur Jr., LICSW, MBA, SEP, C-PATP  |  Clinical Director, District Counseling and Psychotherapy

Confidentiality Notice: This page provides educational information only and does not establish a therapist-client relationship. For a confidential consultation, call District Counseling and Psychotherapy at 202-641-5335.

General Information Deeper Dive for Healthcare Workers

Your Guide to Psychedelic Integration Therapy in Washington DC

This guide explores psychedelic treatment options and integration therapy in Washington DC. It shows how professional support can help you process your psychedelic experiences and heal from trauma.

Meet Joseph LaFleur — Certified Psychedelic Assisted Therapy Provider

Joseph LaFleur specializes in psychedelic integration therapy. He helps people process their psychedelic experiences at District Counseling and Psychotherapy in Washington DC. Joseph is certified, and he uses his training to help clients recover and grow.

His qualifications:

• Certified Psychedelic-Assisted Therapy — Integrative Psychiatric Institute
• Somatic Experiencing Therapy — Somatic Experiencing Trauma Institute (SETI)
• Psychoanalytic Psychotherapy — Washington Baltimore Center for Psychoanalysis
• Licensed Independent Clinical Social Worker (LICSW)

Joseph's training makes him one of the leading psychedelic integration therapists in Washington DC.

What Is Psychedelic Integration Therapy?

Psychedelic integration therapy helps you understand insights from your psychedelic experiences. Your therapist gives you a safe space to explore your feelings and build practical strategies for growth. Without integration, valuable experiences can fade away without leading to lasting change.

Why Integration Therapy Matters

As attitudes toward psychedelics change and more research comes out, more people want support to understand their experiences. This therapy bridges the gap between the experience itself and long-term change. It is valuable for people working through trauma, depression, anxiety, and questions about meaning and purpose.

Ketamine-Assisted Therapy and Suicidal Thoughts

Ketamine-assisted therapy (KAP) has shown real promise in reducing suicidal thoughts, especially for people whose depression has not responded to other treatments. It can bring quick relief, often within hours. This fast response matters because it opens a window for people to engage more fully with ongoing mental health care and can offer renewed hope.

MDMA and PTSD

MDMA-assisted therapy is one of the most promising new treatments for severe PTSD. It is not yet FDA-approved, and MDMA remains a controlled substance available mainly through research studies. Large clinical trials have shown that many participants no longer met the criteria for PTSD after treatment. If you have had this experience in a research or legal setting, integration therapy can help you process what came up.

Psilocybin and Depression

Psilocybin therapy is being studied as a treatment for depression that has not responded to other approaches. Research from major universities shows that it can bring meaningful mood improvement, sometimes after just one or two guided sessions. Psilocybin remains a controlled substance in most places. Integration therapy for people who have already had a psilocybin experience is legal and available.

Who Can Benefit?

Psychedelic integration therapy can help:

• People who took part in legal clinical trials
• People who attended legal ceremonies or had personal psychedelic experiences
• Anyone preparing for a future psychedelic session
• People dealing with lingering effects from past use

Preparing for an Experience

Good preparation makes a real difference. It includes setting a clear intention, talking through fears or worries, thinking about the right setting and support, and reviewing any health risks with a professional beforehand.

Integrating the Experience Afterward

Integration is an ongoing process, not a single conversation. In the days and weeks right after an experience, many people feel open and emotionally sensitive. In the months that follow, the work shifts to holding onto insights while returning to everyday life. Over time, the goal is for new perspectives to become a lasting part of how you think, feel, and act. Helpful tools include talking it through with a therapist, journaling, mindfulness, movement, and connecting with others who understand.

The Role of the Therapist

A good integration therapist understands both traditional mental health care and the unique territory of psychedelic experiences. This helps you make sense of complex emotions, work through spiritual or unusual insights, and turn what you learned into everyday, practical change.

A Note on Legal Status

Ketamine can legally be given in medical settings. MDMA and psilocybin remain controlled substances in most places and are generally available only through approved research. District Counseling and Psychotherapy provides integration therapy — talking through and processing your experience — and does not supply, administer, or facilitate access to any controlled substance.

Conclusion

Psychedelic integration therapy is a valuable process for anyone who wants to understand and use a psychedelic experience for real, lasting growth. With Joseph LaFleur's guidance at District Counseling and Psychotherapy in Washington DC, you can navigate this journey with expert, compassionate support.

Frequently Asked Questions

What is psychedelic integration therapy?

It helps you take the insights and feelings from a psychedelic experience and turn them into lasting change in your daily life. Without this work, even powerful experiences can fade without creating real change.

Who can benefit from this therapy in Washington DC?

People who joined legal clinical trials, attended legal ceremonies, had a personal experience, are preparing for a future session, or are still processing effects from the past. It is especially helpful for trauma, depression, anxiety, and life-meaning questions.

Are ketamine, MDMA, and psilocybin legal?

Ketamine can be legally given in medical settings. MDMA and psilocybin remain controlled substances and are mainly available through research studies. District Counseling and Psychotherapy offers integration therapy only and does not provide or facilitate access to controlled substances.

What are Joseph LaFleur's qualifications?

He is a Certified Psychedelic Assisted Therapy Provider, trained in Somatic Experiencing and Psychoanalytic Psychotherapy, and is a Licensed Independent Clinical Social Worker (LICSW).

---

Ready to integrate your experience?
Call 202-641-5335 or visit districtcounseling.com to schedule a consultation.

Understanding Psychedelic Therapies: A Clinical Overview

This section reviews the neuropharmacology and clinical evidence behind ketamine-, MDMA-, and psilocybin-assisted approaches, and the role of structured integration therapy in sustaining treatment gains. It is intended for clinicians, referring providers, and other healthcare professionals evaluating psychedelic-adjacent care pathways for their patients.

Ketamine-Assisted Therapy: Mechanism of Action

Ketamine functions primarily as a non-competitive NMDA receptor antagonist, modulating glutamatergic signaling implicated in mood regulation and synaptic plasticity. NMDA receptor blockade triggers a downstream cascade — including AMPA receptor activation and increased BDNF (brain-derived neurotrophic factor) signaling — that promotes synaptogenesis and rapid neuroplastic remodeling. This mechanism is distinct from monoaminergic antidepressants and underlies ketamine's characteristically rapid antidepressant response, often within hours rather than weeks.

Ketamine and Suicidality

Clinical studies consistently demonstrate rapid reduction in suicidal ideation following ketamine administration, frequently within hours of dosing, independent of overall antidepressant response trajectory. This rapid effect is clinically significant for acute risk management, providing a window in which patients can engage more fully with concurrent psychotherapeutic and psychiatric care. Ketamine's safety profile is favorable when administered with appropriate screening, dosing protocols, and cardiovascular monitoring, though careful attention to dissociative effects and abuse potential is warranted in ongoing treatment planning.

Neuroplasticity as a Therapeutic Substrate

Neuroplasticity — the brain's capacity to reorganize synaptic connections in response to experience — is central to recovery from depression and trauma-related conditions. Ketamine-induced neuroplastic windows create a time-limited period of heightened synaptic flexibility during which new cognitive and emotional patterns are more readily encoded. This is the clinical rationale for pairing pharmacological intervention with concurrent or closely timed integration therapy: the neuroplastic window provides an opportunity, but psychotherapeutic processing is what determines whether new patterns are consolidated into durable change.

MDMA-Assisted Therapy: Neurobiological Basis

MDMA acts primarily by promoting the release of serotonin, dopamine, and norepinephrine while also increasing circulating oxytocin. Functionally, this produces transient downregulation of amygdala reactivity alongside increased activity in regions associated with self-referential processing and fear extinction, allowing traumatic material to be revisited with reduced physiological threat response. This altered fear-processing state is theorized to widen the window of tolerance during trauma-focused psychotherapy, facilitating engagement with material that would otherwise be too dysregulating to process safely.

Phase 3 trials conducted by the Multidisciplinary Association for Psychedelic Studies (MAPS) reported that approximately 67% of participants receiving MDMA-assisted therapy no longer met diagnostic criteria for PTSD post-treatment, compared to 32% in the placebo-with-therapy arm. The FDA has granted MDMA-assisted therapy for PTSD Breakthrough Therapy designation, though full approval has faced regulatory setbacks, and MDMA remains a Schedule I substance available primarily through research protocols.

Psilocybin-Assisted Therapy: Receptor Dynamics

Psilocybin is dephosphorylated in vivo to its active metabolite, psilocin, which acts as a partial agonist at serotonin 5-HT2A receptors, with additional affinity for 5-HT1A and 5-HT2C sites. 5-HT2A agonism is associated with altered cortical connectivity patterns, including disruption of default mode network activity — a pattern hypothesized to underlie the acute alterations in self-referential processing and rigid cognitive patterning characteristic of depressive states.

Neuroplasticity and Neurogenesis

Preclinical research indicates psilocybin promotes dendritic spine formation and may support hippocampal neurogenesis, mechanisms consistent with its capacity to facilitate durable shifts in mood and cognitive flexibility. Clinical trials from Johns Hopkins University and Imperial College London have reported rapid and sustained antidepressant effects in major depressive disorder, with benefit frequently observed after one or two supported dosing sessions and persistence of effect reported at multi-month follow-up in several cohorts. Psilocybin remains a Schedule I substance in most jurisdictions; clinical access remains largely limited to research and expanded-access frameworks.

Integration Therapy as the Mechanism of Durable Change

Across all three agents, the acute pharmacological and neuroplastic effects are time-limited; sustained clinical benefit depends substantially on structured integration work following the dosing experience. Integration therapy addresses cognitive consolidation of insights, affective processing of material that surfaces during or after sessions, somatic processing of bodily sensations and trauma activation, and behavioral translation of insight into concrete life change. Research published in the Journal of Psychopharmacology associates structured integration support with improved and more durable therapeutic outcomes relative to dosing sessions without integration support.

Scope of Practice and Referral Considerations

District Counseling and Psychotherapy provides preparation and integration psychotherapy and does not administer, prescribe, or facilitate access to controlled substances. For ketamine care specifically, the practice coordinates with licensed medical providers responsible for screening, dosing, and monitoring. Referring clinicians considering integration therapy as an adjunct to ketamine treatment, or supporting patients with prior legal or research-based MDMA or psilocybin exposure, may contact the practice directly to discuss coordinated care.

---

Considering a referral or coordinated care?
Call 202-641-5335 or visit districtcounseling.com.

Joseph W. LaFleur Jr., LICSW, MBA, SEP, C-PATP is the Clinical Director of District Counseling and Psychotherapy in Washington, DC. He is a Certified Psychedelic Assisted Therapy Provider (C-PATP) and specializes in men's mental health, LGBTQ+ affirming care, somatic healing, and psychedelic-assisted therapy integration. Licensed in DC, MD, VA, NJ, and NY.